Alternation in the Human Microbiome With Commonly Used Topical Medications
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03437005|
Recruitment Status : Recruiting
First Posted : February 19, 2018
Last Update Posted : April 28, 2021
The global aim of this study is to investigate how the human microbiome changes from baseline with commonly used topical medications such as topical antifungals, low to mid potency topical steroids and emollients.
The specific aims are as follows:
- Investigate whether ketoconazole cream, a commonly used topical antifungal, causes alterations in the human skin microbiome with short-term use.
- Investigate whether desonide 0.05 % ointment, a commonly used low potency topical steroid, alters the human microbiome with short-term use.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Desonide 0.05% Drug: Ketoconazole 2%||Phase 1|
The microorganisms present on human skin influence human health and disease. Older methods of studying the skin microbiota, such as culture based techniques, favored bacteria, which readily grew under standard laboratory conditions, compared to current molecular approaches, which have shown a greater diversity of skin microbiota. Human skin is a large organ that contains a wide range of physiological and topographical diversity. Distinct niches exist which predispose certain areas, such as hairy, moist underarms to a different bacterial community from dry, smooth sites, such as forearms. Given that the skin is a critical barrier between the body's internal environment and the external environment, characterization of the microbiota of the skin may provide insight into the balance between skin health and disease.
Certain inflammatory skin diseases, such as seborrheic dermatitis, atopic dermatitis and psoriasis, have characteristic sites of involvement. The NIH funded Human Microbiome Project (HMP) aims to characterize the human microbiota and its role in health and disease. Recent research by the HMP showed that certain sites, such as the antecubital and popliteal fossa, sites commonly affected in atopic dermatitis, shared similar groups of organisms and distinct microbial communities. Sebaceous sites, commonly affected in seborrheic dermatitis, also shared similar microbial communities. In addition, Kong et al., showed that changes in microbial communities were temporally associated with disease flares in atopic dermatitis patients. Changes in the microbial communities in atopic dermatitis patients were not only associated with disease flares, but were also associated with whether the patient received treatment with topical medications, including antimicrobial or anti-inflammatory medications, during flares. These findings suggest that communities of microbes are important in the initiation and perpetuation of certain skin diseases and that the topical medications used in treatment of these diseases have an important role, which may be related to their alteration of the microbiome.
The most commonly used treatments in dermatology include topical steroids and topical antifungals, which have long established safety and efficacy. Understanding the changes that these topical medications cause in the human microbiome will provide further insight into their role in the treatment of certain skin diseases and may assist us in developing new therapies in the future.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The patient will be randomized to one of two groups, with one group receiving ketoconazole cream and the other receiving desonide ointment.|
|Masking:||Double (Participant, Investigator)|
|Masking Description:||Investigator and subject will be blinded.|
|Primary Purpose:||Basic Science|
|Official Title:||Alterations in the Human Microbiome With Commonly Used Topical Medications|
|Actual Study Start Date :||January 28, 2013|
|Estimated Primary Completion Date :||September 28, 2026|
|Estimated Study Completion Date :||September 28, 2026|
Experimental: Desonide 0.05%
Low potency steroid topical medication applied to specific locations on the face and extremities, twice daily for two weeks
Drug: Desonide 0.05%
Desonide 0.05% ointment topically twice daily for two weeks
Experimental: Ketoconazole 2%
Antifungal topical medication applied to specific locations on the face and extremities, twice daily for two weeks
Drug: Ketoconazole 2%
Ketoconazole 2% cream topically twice daily for two weeks
- Number of bacteria per each species [ Time Frame: 2 weeks after initial dispensing ]Percentage of various bacteria present on each skin site
- Number of species at test sites [ Time Frame: 2 weeks after initial dispensing ]The taxonomic diversity and evenness of each skin site's microbiome
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03437005
|Contact: Emanual Maverakis, MDemail@example.com|
|Contact: Lauren Downingfirstname.lastname@example.org|
|United States, California|
|University of California, Davis, Department of Dermatology||Recruiting|
|Sacramento, California, United States, 95816|
|Contact: Emanual Maverakis, MD 916-734-8254 email@example.com|
|Contact: Lauren Downing 916-551-2635 firstname.lastname@example.org|
|Principal Investigator:||Emanual Maverakis, MD||UC Davis|